The candidate drug AP1189 is being developed for the treatment of psoriatic arthritis and has shown positive effects in several preclinical disease models. The primary purpose of the Clinical Phase I study is to evaluate the safety and tolerability of AP1189 in healthy subjects, as well as to study its pharmacokinetics, i.e. how it is absorbed and metabolized (broken down) in the body. The timeframe for the implementation of the Phase I study is approximately nine months and the results are expected to be reported during 2017.
CEO Jeppe Øvlesen comments:
– The submission of the application is a very important milestone for SynAct and means that we are another step closer to the implementation of the planned Phase I clinical study.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Telephone: +45 40 15 66 69
E-mail: [email protected]
This is information that SynAct Pharma AB is obliged to disclose under the EU’s market abuse regulation. The information was submitted by the above contact person for publication on 9 December 2016.
SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.